Related Experiment Video
Updated: Jul 18, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors
George Pan1, Michael Kilby, Jay M McDonald
1Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Highly Active Antiretroviral Therapy (HAART) drugs like zidovudine (AZT) stimulate bone breakdown, leading to osteopenia. This study confirms NRTI drug-induced osteoclastogenesis is RANKL-dependent and suggests an assay for assessing bone loss risk in patients.
Area of Science:
- Bone Biology
- Pharmacology
- Immunology
Background:
- Osteopenia is a frequent complication of Highly Active Antiretroviral Therapy (HAART).
- The precise mechanisms by which HAART impacts bone metabolism remain largely unelucidated.
- Previous research indicated zidovudine (AZT) stimulates osteoclastogenesis and causes osteopenia in mice.
Purpose of the Study:
- To investigate the effects of nucleoside reverse transcriptase inhibitors (NRTIs) on osteoclastogenesis and bone metabolism.
- To determine the role of Receptor Activator of Nuclear Factor kappa-B Ligand (RANKL) in NRTI-induced osteoclastogenesis.
- To evaluate the potential of an in vitro assay for predicting bone turnover in patients on HAART.
Main Methods:
- In vitro osteoclastogenesis assays using murine and human osteoclast precursors.
- Administration of NRTI drugs (AZT, ddl, 3TC) to mice to induce osteopenia.
- Blocking experiments using osteoprotegerin (OPG) and testing of alendronate and tumor necrosis factor-alpha (TNF-α).
- Assessment of osteoblast and osteoclast parameters in vivo.
Main Results:
- AZT, ddl, and 3TC stimulated osteoclastogenesis in vitro and induced osteopenia in mice.
- NRTI-induced osteoclastogenesis was dependent on RANKL and could be blocked by OPG.
- Alendronate and TNF-α did not inhibit AZT-induced osteoclastogenesis in vitro.
- Osteopenia was associated with increased osteoclast activity, not osteoblast activity.
- AZT-induced osteoclastogenesis in human cells was RANKL-dependent.
Conclusions:
- NRTIs commonly used in HAART can directly stimulate osteoclastogenesis, contributing to osteopenia.
- The RANKL pathway is critical for NRTI-induced bone resorption.
- An in vitro assay using human peripheral blood mononuclear cells may serve as a valuable tool for assessing bone turnover and osteopenia risk in HIV patients undergoing HAART.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Osteoclasts in Bone Remodeling
Inhibitors of Virion Maturation and Assembly
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
